Developing a drug for late-stage brain cancer. Brain tumor clinical trial underway for AA3 or Grade 3 glioma.
Location: Canada
Total raised: $103.5M
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.10.2020 | Series A | $71M | H.I.G. Bio... |
| 20.08.2015 | Series A | $32.5M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 19.01.2022 | Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reach... | - Phase 3 STELLAR trial evaluating eflornithine in patients with recurrent anaplastic astrocytoma - ... | globenewsw... |
| 22.10.2020 | Orbus Therapeutics Expands Series A Financing to $71 Million... | - | abingworth... |
| 21.08.2015 | Orbus gets $32.5M to repurpose hirsutism drug for brain canc... | Orbus has found that eflornithine can improve survival rates among patients with newly diagnosed or ... | medcitynew... |
| 20.08.2015 | Orbus Therapeutics Secures $32.5M | PALO ALTO, CA, Orbus Therapeutics today announced the completion of a $32.5 million Series A finan... | vcnewsdail... |
| 20.08.2015 | Orbus Therapeutics Completes $32.5M Series A Financing | Orbus Therapeutics Inc., a Palo Alto, CA-based clinical-stage biopharmaceutical company, completed a... | finsmes.co... |
| - | Orbus gets $32.5M to repurpose hirsutism drug for brain canc... | An already-approved drug used to treat excess facial hair and sleeping sickness may have an importan... | medcitynew... |